The Super Bowl, a spectacle of athleticism and entertainment, took an unexpected turn this year when Serena Williams appeared in a commercial that ignited a firestorm of controversy. Viewers anticipating a triumphant return to the court were instead presented with an advertisement for a weight-loss drug, a jarring shift that left many feeling deeply disappointed.
The commercial featured the 44-year-old tennis icon utilizing a GLP-1 medication, readily ordering more through an app, and hinting at a future pill form. Williams spoke of benefits like reduced knee stress, stabilized blood sugar, and improved cholesterol, positioning the drug as a comprehensive health solution. But for a significant number of fans, this framing did little to quell their unease.
The backlash was immediate and intense, fueled by the perception that a symbol of strength and resilience – particularly for women – was succumbing to societal pressures surrounding body image. Many questioned why a champion of empowerment would promote a product centered on achieving thinness.
“Serena Williams can be doing so much to champion women’s sports or the importance of body positivity but instead is pushing a weight loss drug in her retirement,” one viewer lamented, echoing a sentiment felt by many. Others expressed concern over the advertisement’s reach, arguing that promoting such medications during a widely-watched event like the Super Bowl felt irresponsible.
Williams’ journey with the medication began after the birth of her second child, Adira River Ohanian, in 2023. She openly shared her frustration with being unable to lose weight despite rigorous training and a healthy diet, describing it as a deeply challenging experience unlike any she’d faced before. She began using the drug in 2024, after completing breastfeeding.
She revealed losing over 30 pounds in a year, framing the transformation as both liberating and the result of dedicated effort. However, critics argue that showcasing this on a massive platform like the Super Bowl normalizes the medicalization of weight loss and potentially harms body image perceptions.
The situation is further complicated by Williams’ personal connections. Her husband, Alexis Ohanian, is an investor in the telehealth provider Ro and holds a position on its board, a detail that, while disclosed, has raised questions about potential conflicts of interest.
For many, the advertisement felt particularly poignant given Williams’ history. A Black woman whose powerful physique was once subjected to scrutiny, she now endorses a product promising a smaller frame, a turn of events that struck a discordant note with her legacy of challenging conventional beauty standards.
The controversy surrounding the commercial highlights a broader cultural debate about body image, access to healthcare, and the increasing prevalence of GLP-1 medications. It raises important questions about the messages we send, particularly to young people, about health, beauty, and self-worth.
